TP53 and head and neck squamous cell carcinoma: Relevant to the results of this study are the findings obtained from the recent multiepitope wt sequence p53 peptide vaccine clinical trial5, the vaccination of patients with HNSCC resulted in an increased frequency of tet264–272+ CD8+ T cells in their peripheral circulation and decreased levels of Treg.